Status:
COMPLETED
Blood Sample Collection for Experimental Blood Test to Track Liver Cancer
Lead Sponsor:
Thomas Jefferson University
Conditions:
Hepatocellular Carcinoma
Eligibility:
All Genders
18+ years
Brief Summary
This study investigates if an experimental blood test can help predict how well cancer will remain under control with treatment. Ther experimental blood test involves measuring mircoRNAs. MicroRNAs ar...
Eligibility Criteria
Inclusion
- Provide signed and dated informed consent form
- Willing to comply with all study procedures and be available for the duration of the study
- Definite diagnosis of hepatocellular carcinoma established (by standard radiographic or histologic criteria)
- Felt to be reasonable candidate for liver transplantation, potentially contingent on success of down-staging therapy
Exclusion
- Either active or recent solid organ cancer other than hepatocellur carcinoma (HCC) within the last 5 years, unless determined by transplant hepatology team not to represent contra-indication to liver transplantation
- Contra-indication to LRT (as assessed by interventional radiologist, for example severe thrombocytopenia, severe vascular disease precluding access, etc)
- History of prior liver transplantation
- Active or prior systemic therapy for HCC
Key Trial Info
Start Date :
December 3 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 9 2023
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT04720430
Start Date
December 3 2019
End Date
November 9 2023
Last Update
April 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, United States, 19107